000165964 001__ 165964
000165964 005__ 20240229133516.0
000165964 0247_ $$2doi$$a10.1055/a-1290-7926
000165964 0247_ $$2pmid$$apmid:33212540
000165964 0247_ $$2ISSN$$a0015-8151
000165964 0247_ $$2ISSN$$a0340-1618
000165964 0247_ $$2ISSN$$a0367-2239
000165964 0247_ $$2ISSN$$a0936-6652
000165964 0247_ $$2ISSN$$a1433-5972
000165964 0247_ $$2ISSN$$a1438-9010
000165964 0247_ $$2ISSN$$a1438-9029
000165964 037__ $$aDKFZ-2020-02513
000165964 041__ $$aeng
000165964 082__ $$a610
000165964 1001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b0$$eFirst author$$udkfz
000165964 245__ $$aLung Cancer Screening by Low-Dose Computed Tomography - Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting [Lungenkrebs-Screening mittels Niedrigdosis-Computertomografie – Teil 1: Erwarteter Nutzen, mögliche Schäden und Kriterien für die Eignung und das Targeting der Bevölkerung].
000165964 260__ $$aStuttgart [u.a.]$$bThieme$$c2021
000165964 3367_ $$2DRIVER$$aarticle
000165964 3367_ $$2DataCite$$aOutput Types/Journal article
000165964 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634132529_10604$$xReview Article
000165964 3367_ $$2BibTeX$$aARTICLE
000165964 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165964 3367_ $$00$$2EndNote$$aJournal Article
000165964 500__ $$a#EA:C020#LA:E010#2021 May;193(5):527-536
000165964 520__ $$aTrials in the USA and Europe have convincingly demonstrated the efficacy of screening by low-dose computed tomography (LDCT) as a means to lower lung cancer mortality, but also document potential harms related to radiation, psychosocial stress, and invasive examinations triggered by false-positive screening tests and overdiagnosis. To ensure that benefits (lung cancer deaths averted; life years gained) outweigh the risk of harm, lung cancer screening should be targeted exclusively to individuals who have an elevated risk of lung cancer, plus sufficient residual life expectancy. Overall, randomized screening trials show an approximate 20 % reduction in lung cancer mortality by LDCT screening. In view of declining residual life expectancy, especially among continuing long-term smokers, risk of being over-diagnosed is likely to increase rapidly above the age of 75. In contrast, before age 50, the incidence of LC may be generally too low for screening to provide a positive balance of benefits to harms and financial costs. Concise criteria as used in the NLST or NELSON trials may provide a basic guideline for screening eligibility. An alternative would be the use of risk prediction models based on smoking history, sex, and age as a continuous risk factor. Compared to concise criteria, such models have been found to identify a 10 % to 20 % larger number of LC patients for an equivalent number of individuals to be screened, and additionally may help provide security that screening participants will all have a high-enough LC risk to balance out harm potentially caused by radiation or false-positive screening tests. · LDCT screening can significantly reduce lung cancer mortality. · Screening until the age of 80 was shown to be efficient in terms of cancer deaths averted; in terms of LYG relative to overdiagnosis, stopping at a younger age (e. g. 75) may have greater efficiency. · Risk models may improve the overall net benefit of lung cancer screening.· Kaaks R, Delorme S. Lung Cancer Screening by Low-Dose Computed Tomography - Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting. Fortschr Röntgenstr 2020; DOI: 10.1055/a-1290-7926.
000165964 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000165964 588__ $$aDataset connected to CrossRef, PubMed,
000165964 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b1$$eLast author$$udkfz
000165964 773__ $$0PERI:(DE-600)2031079-1$$a10.1055/a-1290-7926$$gp. a-1290-7926$$n5$$p527-536$$tRöFo$$v193$$x1438-9010$$y2021
000165964 909CO $$ooai:inrepo02.dkfz.de:165964$$pVDB
000165964 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000165964 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000165964 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000165964 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000165964 9141_ $$y2021
000165964 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-28$$wger
000165964 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bROFO-FORTSCHR RONTG : 2018$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-28
000165964 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-28
000165964 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000165964 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000165964 980__ $$ajournal
000165964 980__ $$aVDB
000165964 980__ $$aI:(DE-He78)C020-20160331
000165964 980__ $$aI:(DE-He78)E010-20160331
000165964 980__ $$aUNRESTRICTED